Neuren Pharmaceuticals Limited (OTCMKTS:NURPF – Get Free Report) was the recipient of a significant decline in short interest in the month of July. As of July 15th, there was short interest totaling 152,860 shares, a decline of 62.7% from the June 30th total of 409,938 shares. Based on an average trading volume of 2 shares, the short-interest ratio is presently 76,430.0 days.
Neuren Pharmaceuticals Price Performance
Neuren Pharmaceuticals stock opened at C$13.46 on Monday. The business has a 50 day moving average price of C$10.54 and a two-hundred day moving average price of C$9.99. Neuren Pharmaceuticals has a 12 month low of C$7.70 and a 12 month high of C$14.80.
About Neuren Pharmaceuticals
Neuren Pharmaceuticals (OTCMKTS:NURPF) is an Australian-based clinical-stage biopharmaceutical company focused on developing innovative peptide-based therapeutics for the treatment of neurodevelopmental and neurodegenerative disorders. The company’s research efforts center on addressing unmet medical needs in conditions such as Rett syndrome, Fragile X syndrome and Angelman syndrome. Neuren is publicly traded on the Australian Securities Exchange and maintains an over-the-counter listing in the United States, reflecting its commitment to global capital markets and investor engagement.
The company’s lead candidate, trofinetide (NNZ-2566), is a synthetic analogue of a naturally occurring peptide that has been evaluated in late-stage clinical trials for Rett syndrome and Fragile X syndrome.
See Also
- Five stocks we like better than Neuren Pharmaceuticals
- These 3 AI Winners Don’t Sell the Tech—They Use It
- RTX and Lockheed Earnings: Can Strong Guidance Reset the Defense Trade?
- These 4 Earnings Reports Expose the Market’s Growing Economic Divide
- Broadcom May Be the Biggest Winner From Alphabet’s Earnings
Receive News & Ratings for Neuren Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Neuren Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
